ST. LOUIS, July 8, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that the first procedure with its Niobe® ES magnetic navigation system has been performed in Japan. Dr. Kohei Yamashiro of Takatsuki General Hospital completed a cardiac ablation on a patient with ventricular tachycardia, noting, in particular, the improved navigation of the ablation catheter and ease of mapping with the Niobe system compared to manual methods for lesion creation.
"We are excited to be the first institution in Japan to offer this unique, innovative approach to treating complex cardiac arrhythmias, which continue to rise in prevalence at a rapid rate with our aging population," said Dr. Yamashiro. "The Niobe system provides greater visibility and precise control of the ablation catheter, as well as significantly increased safety, which I expect to translate into improved outcomes for my patients." Dr. Yamashiro has more than 10 procedures scheduled for the Niobe system's first two weeks of operation.
Takatsuki General Hospital is located near Osaka, Japan and recently underwent a complete renovation to support the latest medical advances and provide higher quality, more integrated patient services. Installation of the Niobe system was completed in the second quarter, as Dr. Yamashiro, its primary operator, received comprehensive training at Stereotaxis sites in the U.S. The hospital held a grand opening lecture on the Niobe system lab July 3, featuring presentations by Dr. Yamashiro and Dr. Hiroshi Nakagawa, a prominent electrophysiologist, who has educated Japanese physicians and government officials on the use of Stereotaxis technologies.
"We have envisioned this day for some time and are very pleased to see it come to fruition," said William C. Mills, Stereotaxis' Chief Executive Officer. "Our momentum continues to build in Japan as we set our sights on becoming the region's first choice in the treatment of complex electrophysiology cases."
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis' systems have received regulatory clearance in the U.S., European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received U.S. clearance. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
CONTACT: Press Contact: Martin Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300